These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 15232748)

  • 41. Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity.
    Ali R; Thomas P; White J; McGregor C; Danz C; Gowing L; Stegink A; Athanasos P
    Drug Alcohol Rev; 2003 Dec; 22(4):425-31. PubMed ID: 14660132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
    Haile CN; Kosten TA; Kosten TR
    Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence.
    Kakko J; von Wachenfeldt J; Svanborg KD; Lidström J; Barr CS; Heilig M
    Biol Psychiatry; 2008 Jan; 63(2):172-7. PubMed ID: 17850768
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Naltrexone-mediated opiate detoxification: a matter of terminology!
    Johnson TS; Carr M
    Addict Biol; 2003 Sep; 8(3):267-9. PubMed ID: 13129827
    [No Abstract]   [Full Text] [Related]  

  • 45. Naltrexone for probationers and parolees.
    O'Brien C; Cornish JW
    J Subst Abuse Treat; 2006 Sep; 31(2):107-11. PubMed ID: 16919734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment.
    Tait RJ; Ngo HT; Hulse GK
    J Subst Abuse Treat; 2008 Sep; 35(2):116-24. PubMed ID: 17931824
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Naltrexone treatment in a jail work-release program.
    Brahen LS; Henderson RK; Capone T; Kordal N
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):49-52. PubMed ID: 6469937
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Efficacy of naltrexone in the treatment of alcohol dependence disorder in women].
    Ponce G; Sánchez-García J; Rubio G; Rodríguez-Jiménez R; Jiménez-Arriero MA; Palomo T
    Actas Esp Psiquiatr; 2005; 33(1):13-8. PubMed ID: 15704026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study.
    Jarvis BP; DeFulio A; Long L; Holtyn AF; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    J Subst Abuse Treat; 2018 Feb; 85():56-60. PubMed ID: 28161142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Naltrexone implants as treatment for heroin dependence: part I.
    Byrne A; Graham G; Hallinan R; Murnion B
    Addict Biol; 2005 Jun; 10(2):201; author reply 201-2. PubMed ID: 16191674
    [No Abstract]   [Full Text] [Related]  

  • 51. [Long-acting naltrexone--a new way out of opiate addiction?].
    Stavseth LS; Kunøe N; Tanum L
    Tidsskr Nor Laegeforen; 2013 Nov; 133(21):2231-2. PubMed ID: 24226324
    [No Abstract]   [Full Text] [Related]  

  • 52. Naltrexone in drug addiction: significance in the prevention of relapse.
    Hoque MM; Hossain KJ; Kamal MM; Akhtaruzzaman M
    Mymensingh Med J; 2009 Jan; 18(1 Suppl):S56-65. PubMed ID: 19377433
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Naltrexone-assisted rapid methadone discontinuation: a pilot study.
    Camarasa X; Khazaal Y; Besson J; Zullino DF
    Eur Addict Res; 2007; 13(1):20-4. PubMed ID: 17172775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized control trial of group counseling in a naltrexone treatment program.
    Tucker T; Ritter A; Maher C; Jackson H
    J Subst Abuse Treat; 2004 Dec; 27(4):277-88. PubMed ID: 15610829
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial.
    Sullivan MA; Rothenberg JL; Vosburg SK; Church SH; Feldman SJ; Epstein EM; Kleber HD; Nunes EV
    Am J Addict; 2006; 15(2):150-9. PubMed ID: 16595353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
    Koch AL; Arfken CL; Schuster CR
    Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review.
    Johansson BA; Berglund M; Lindgren A
    Addiction; 2006 Apr; 101(4):491-503. PubMed ID: 16548929
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ultra-rapid opiate detoxification: from clinical applications to basic science.
    Streel E; Verbanck P
    Addict Biol; 2003 Jun; 8(2):141-6. PubMed ID: 12850772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Naltrexone in the therapeutic relation in cases of opioid abuse and dependence].
    Liffredo C; Gallino G
    Minerva Med; 1993 Dec; 84(12):687-92. PubMed ID: 8127459
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments.
    Kreek MJ; Bart G; Lilly C; LaForge KS; Nielsen DA
    Pharmacol Rev; 2005 Mar; 57(1):1-26. PubMed ID: 15734726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.